- Programs & Services
- Cost Management
- Specialty Management
- Care Management
- Member Engagement
- Health Plan Client Engagement
Multiple chimeric antigen receptor (CAR) T-cell therapy approvals are anticipated for the gene therapy drug pipeline from this year through 2025. Other therapies under consideration for approval target respiratory syncytial virus-mediated lower respiratory tract disease, knee osteoarthritis, neovascular (wet) age-related macular degeneration, hemophilia A, hemophilia B and different cancers including metastatic melanoma.
In our periodic gene therapy pipeline update report, we share information about treatments that the U.S. Food and Drug Administration (FDA) may review and approve.
The gene therapy drug pipeline is constantly shifting due to the success — or lack thereof — of clinical trials and other important data.